Fungal endophytes affect plant response to leaf litter with contrasting chemical traits

Abstract Plant litter decomposition is a crucial process of nutrient cycling within ecosystems. However, many studies have shown that, apart from its several beneficial effects, organic matter decomposition can be disadvantageous to seed germination, seedling growth, and physiological activity of plants. Litter decomposition was reported to affect both plants and their associated soil microbial communities. The aim of this work was to test the relationships between seed-associated endophytic fungi on the either positive or negative plant's response to different litter types. Leaf material of four species was collected and used in a decomposition experiment inside a growth chamber for 120 days. The plant growth experiment was set in a greenhouse using Trifolium repens and Triticum durum with and without their associated endophytic fungi in the presence of the different litter species at two decay levels (fresh litter and after 120 days of decomposition). Results demonstrated that fresh litter exerted a strong inhibition effect on the plant total biomass when compared to decomposed litter. Moreover, seed-associated endophytic fungi enhanced the inhibitory effect of litter in the observed experimental conditions. The removal of seed-associated endophytic fungi improved the capacity of tested plants to resist to litter inhibitory effect

Computer simulations of particle packing

Computer code has been developed to rapidly simulate the random packing of disks and spheres in two and three dimensions. Any size distribution may be packed. The code simulates varying degrees of inter particle conditions ranging from sticky to free flowing. The code will also calculate the overall packing density, density distributions, and void size distributions (in two dimensions). An important aspect of the code is that it is written in C++ and incorporates a user-friendly graphical interface for standard Macintosh and Power PC platforms. Investigations as to how well the code simulates the realistic random packing have begun. The code has been developed in consideration of the problem of filling a container (or die) with spray-dried granules of ceramic powder (represented by spheres). Although not presented here, the futuristic goal of this work is to give users the ability to predict homogeneity of filled dies prior to dry pressing. Additionally, this software has educational utility for studying relationships between particle size distributions and macrostructures

Deformation and Grain Growth of Low-Temperature-Sintered High-Purity Alumina

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/66091/1/j.1151-2916.1990.tb06489.x.pd

Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma

Multiple myeloma (MM) is a malignancy of plasma cells whose antibody secretion creates proteotoxic stress relieved by the N-end rule pathway, a proteolytic system that degrades N-arginylated proteins in the proteasome. When the proteasome is inhibited, protein cargo is alternatively targeted for autophagic degradation by binding to the ZZ-domain of p62/ sequestosome-1. Here, we demonstrate that XRK3F2, a selective ligand for the ZZ-domain, dramatically improved two major responses to the proteasome inhibitor bortezomib (Btz) by increasing: i) killing of human MM cells by stimulating both Btz-mediated apoptosis and necroptosis, a process regulated by p62; and ii) preservation of bone mass by stimulating osteoblast differentiation and inhibiting osteoclastic bone destruction. Co-administration of Btz and XRK3F2 inhibited both branches of the bimodal N-end rule pathway exhibited synergistic anti-MM effects on MM cell lines and CD138+ cells from MM patients, and prevented stromal-mediated MM cell survival. In mice with established human MM, co-administration of Btz and XRK3F2 decreased tumor burden and prevented the progression of MM-induced osteolytic disease by inducing new bone formation more effectively than either single agent alone. The results suggest that p62-ZZ ligands enhance the anti- MM efficacy of proteasome inhibitors and can reduce MM morbidity and mortality by improving bone health

Long-term outcome of COVID-19 patients treated with helmet noninvasive ventilation vs. high-flow nasal oxygen: a randomized trial

Background: Long-term outcomes of patients treated with helmet noninvasive ventilation (NIV) are unknown: safety concerns regarding the risk of patient self-inflicted lung injury and delayed intubation exist when NIV is applied in hypoxemic patients. We assessed the 6-month outcome of patients who received helmet NIV or high-flow nasal oxygen for COVID-19 hypoxemic respiratory failure. Methods: In this prespecified analysis of a randomized trial of helmet NIV versus high-flow nasal oxygen (HENIVOT), clinical status, physical performance (6-min-walking-test and 30-s chair stand test), respiratory function and quality of life (EuroQoL five dimensions five levels questionnaire, EuroQoL VAS, SF36 and Post-Traumatic Stress Disorder Checklist for the DSM) were evaluated 6 months after the enrollment. Results: Among 80 patients who were alive, 71 (89%) completed the follow-up: 35 had received helmet NIV, 36 high-flow oxygen. There was no inter-group difference in any item concerning vital signs (N = 4), physical performance (N = 18), respiratory function (N = 27), quality of life (N = 21) and laboratory tests (N = 15). Arthralgia was significantly lower in the helmet group (16% vs. 55%, p = 0.002). Fifty-two percent of patients in helmet group vs. 63% of patients in high-flow group had diffusing capacity of the lungs for carbon monoxide < 80% of predicted (p = 0.44); 13% vs. 22% had forced vital capacity < 80% of predicted (p = 0.51). Both groups reported similar degree of pain (p = 0.81) and anxiety (p = 0.81) at the EQ-5D-5L test; the EQ-VAS score was similar in the two groups (p = 0.27). Compared to patients who successfully avoided invasive mechanical ventilation (54/71, 76%), intubated patients (17/71, 24%) had significantly worse pulmonary function (median diffusing capacity of the lungs for carbon monoxide 66% [Interquartile range: 47–77] of predicted vs. 80% [71–88], p = 0.005) and decreased quality of life (EQ-VAS: 70 [53–70] vs. 80 [70–83], p = 0.01). Conclusions: In patients with COVID-19 hypoxemic respiratory failure, treatment with helmet NIV or high-flow oxygen yielded similar quality of life and functional outcome at 6 months. The need for invasive mechanical ventilation was associated with worse outcomes. These data indicate that helmet NIV, as applied in the HENIVOT trial, can be safely used in hypoxemic patients. Trial registration Registered on clinicaltrials.gov NCT04502576 on August 6, 202